Company: NGVT
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001653477-25-000015
Chunk: 1130

Company: Ingevity Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 1130
---
 of cost or market charges associated with restructuring actions, acquisition and other-related income (costs), gain (loss) on sale of strategic investments, loss on CTO resales, CTO supply contract termination charges, and pension and postretirement settlement and curtailment income (charges), net.

99

IndexIngevity CorporationNotes to the Consolidated Financial StatementsDecember 31, 2024

(2) Segment expenses included within the primary measure used by our CODM are included within the below table.Years Ended December 31,202420232022In millions, except per share dataPMPCAPTPMPCAPTPMPCAPTNet sales (1)$609.6 $608.2 $188.6 $586.0 $902.1 $204.0 $548.5 $875.1 $244.7 Less:Cost of sales (2) (3)233.9 515.5 129.9 254.2 743.2 135.2 237.6 614.2 180.0 Selling, general, and administrative expenses (2) (4) 56.8 73.3 22.3 46.1 92.8 22.1 58.8 99.6 28.5 Other income (expense), net (2) (5)0.2 (4.7)(1.2)0.9 (0.4)(2.2)0.1 (0.9)3.8 Segment EBITDA$319.1 $14.7 $35.2 $286.6 $65.7 $44.5 $252.2 $160.4 $40.0 _______________(1) Relates to external customers only. Refer to Note 4 for a reconciliation to consolidated Net sales.(2) Excludes Depreciation and amortization.(3) Inventory charges representing lower of cost or market charges associated with the Performance Chemicals repositioning and restructuring actions were not allocated in the measurement of Performance Chemicals reportable segment profitability used by our CODM. Amounts are included in Cost of sales on the consolidated statements of operations.(4) Includes Research and technical expenses.(5) We have excluded the following items from Other income (expense), net: gain (loss) on sale of strategic investments, loss on CTO